| Similar Articles |
|---|
 |
The Motley Fool
October 18, 2010
Anand Chokkavelu |
There Are Better Opportunities Than Boston Scientific Let's take a look. By the numbers, Abbott, Medtronic, and Johnson & Johnson all look more compelling than Boston Scientific.   |
The Motley Fool
June 13, 2006
Jim Mueller |
Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note. |
The Motley Fool
December 5, 2005
Stephen D. Simpson |
Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note. |
The Motley Fool
January 12, 2006
Stephen D. Simpson |
The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note. |
The Motley Fool
January 29, 2009
Brian Orelli |
No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed. |
The Motley Fool
February 8, 2006
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? Dominion Resources... Goodrich Petroleum... iPass... ITT Educational Services... St. Jude Medical... |
The Motley Fool
April 9, 2010
Brian Orelli |
Is Boston Scientific Turning It Around? Selling off a pair of units could help. |
The Motley Fool
November 11, 2009
Jim Mueller |
This Company Is a Value Stock! Isn't It? A look at Boston Scientific leads to conflicting conclusions. |
The Motley Fool
July 23, 2008
Brian Orelli |
Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down. |
The Motley Fool
May 25, 2005
Stephen D. Simpson |
Stent Wars 2: The Market-Share Menace The battle for drug-coated stent market share between Johnson & Johnson and Boston Scientific may not be as exciting as watching Obi-Wan Kenobi and Anakin Skywalker fight, but the outcome matters for investors. |
The Motley Fool
May 28, 2004
W.D. Crotty |
Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability. |
The Motley Fool
October 14, 2005
Stephen D. Simpson |
Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is. |
The Motley Fool
February 12, 2010
Brian Orelli |
Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year. |
The Motley Fool
April 26, 2006
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Cash Systems... Imation... Matria Healthcare... Star Scientific... Tortoise North American Energy... |
The Motley Fool
February 1, 2010
Brian Orelli |
Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost. |
The Motley Fool
December 6, 2006
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Builders FirstSource... Internet Capital Group... Kirkland's... Orthofix... Smith & Wollensky... |
The Motley Fool
February 3, 2011
Brian Orelli |
Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes. |
The Motley Fool
June 21, 2006
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? E*Trade Financial... Fossil... General Growth Properties... Restoration Hardware... TASER... |
The Motley Fool
January 17, 2006
Stephen D. Simpson |
High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good. |
The Motley Fool
February 7, 2006
Stephen D. Simpson |
Boston Scientific's Big Task The company won the battle for Guidant, but the hard work hasn't even begun. Value is value, and if Boston Scientific proves it can handle the considerable challenges ahead, this could ultimately be a very interesting stock again. |
The Motley Fool
August 12, 2010
Brian Orelli |
Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later. |
The Motley Fool
July 29, 2011
Brian Orelli |
Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last? |
The Motley Fool
January 13, 2006
Stephen D. Simpson |
Once More With Guidant In the ongoing game of tit-for-tat, Boston Scientific ups its bid for Guidant. This battle will ultimately be decided by the 800-pound gorilla that is J&J. Investors, take note. |
BusinessWeek
January 30, 2006
Robert Barker |
Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber. |
The Motley Fool
September 26, 2005
Stephen D. Simpson |
Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors? |
The Motley Fool
June 29, 2006
Jim Mueller |
Guidant, Devices, and Recalls, Oh My! To repair its acquisition's good name, Boston Scientific must quickly fix Guidant's problems. One analyst sees annual growth for Guidant's devices in the 10% to 15% range. No one knows how accurate that will prove to be, but it certainly provides hope for the troubled acquisition. |
The Motley Fool
October 13, 2008
Brian Orelli |
Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier. |
The Motley Fool
June 26, 2009
Brian Orelli |
Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss. |
The Motley Fool
October 20, 2006
Motley Fool Contributors |
Boston Scientific: Fool by Numbers Boston Scientific released third quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
October 2, 2008
Brian Orelli |
Will Johnson & Johnson Ever Get Its Money? For investors, there are a couple of lessons here. First, perhaps more than any other, the health care sector has a lot of lawsuits. |
The Motley Fool
March 1, 2006
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's buying now? Diodes... Fairpoint Communications... Fossil... Mellon Financial... WCI Communities... |
The Motley Fool
February 1, 2005
Stephen D. Simpson |
Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth. |
The Motley Fool
December 13, 2011
Dan Caplinger |
Has Boston Scientific Become the Perfect Stock? Since we looked at Boston Scientific last year, the maker of medical devices has gotten up off the mat and quadrupled its score. |
The Motley Fool
June 20, 2011
Cindy Johnson |
11 Health-Care Stocks Insiders Are Buying What the insiders are doing can tell us a lot. |
The Motley Fool
December 3, 2010
Seth Jayson |
How Boston Scientific May Be Failing You With recent TTM margins all well below historical averages, Boston Scientific has some work to do. |
The Motley Fool
July 21, 2010
Brian Orelli |
Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now. |
The Motley Fool
January 25, 2006
Stephen D. Simpson |
Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note. |
The Motley Fool
May 29, 2008
Brian Orelli |
Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific. |
The Motley Fool
October 23, 2008
Brian Orelli |
Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter. |
The Motley Fool
February 24, 2004
Alyce Lomax |
J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain? |
The Motley Fool
December 26, 2007
Tim Beyers |
Who's Buying Now? Insider purchases: General Growth Properties...Isle of Capri Casinos... NCI Building Systems... Resources Connection... Universal Forest Products... |
The Motley Fool
September 14, 2011
Brian Orelli |
How to Muck Up a Turnaround in 12 and a Half Months Boston Scientific's choice for a new CEO has the potential to really muck up its recovery even further -- if that's even possible. |
The Motley Fool
July 31, 2006
Stephen D. Simpson |
Can Boston Scientific Get It Right? To boost investor confidence, management must first prove itself. |
The Motley Fool
January 11, 2008
Tim Beyers |
Who's Buying Now? Insider trades: Equity One... Goodrich Petroleum... KB Home... ShorTel... |
The Motley Fool
July 1, 2011
Cindy Johnson |
5 Consumer Services Stocks Insiders Are Buying Open-market insider buys are a positive sign. |
The Motley Fool
August 23, 2011
Cindy Johnson |
13 Health-Care Equipment Stocks Insiders Are Buying Folks in the know think these stocks will rise. Should you join them? |
The Motley Fool
November 9, 2009
Brian Orelli |
Guidant: The Gift That Keeps on Giving And not in the good way. Last year, Boston Scientific took a whopping $2.7 billion goodwill writedown because it had to downgrade the value of what it got in acquiring Guidant. |
The Motley Fool
August 6, 2004
Jeff Hwang |
Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share? |
The Motley Fool
May 11, 2011
Brian Orelli |
Boston Scientific Investors' Parting Gift Less than two years in, Elliot is out. |
